CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


We found 7044 result(s)

Recombinant Activated Factor VII for Bleeding in Patients without Inherited Bleeding Disorders

Last Updated: March 22, 2006
Result type: Reports

Recombinant activated factor VII (rFVIIa) is licensed in Canada for the prevention and treatment of bleeding in hemophiliacs, but it is increasingly used to control bleeding in non-hemophilic patients during surgery, or during treatment for severe trauma or intracerebral hemorrhage (ICH). In one clinical trial, there was a significant re...

Chondroitin Sulfate for Interstitial Cystitis

Last Updated: May 24, 2006
Result type: Reports

Chondroitin sulfate solution 2.0% is a glycosaminoglycan (GAG) replenishment therapy instilled into the bladder of GAG-deficient patients with interstitial cystitis (IC). Two non-randomized, uncontrolled pilot studies report improvements in patient-reported symptoms after the use of chondroitin sulfate for one  year. Prospectiv...

Capsule Colonoscopy: PillCam® Colon

Last Updated: October 23, 2007
Result type: Reports

The PillCam® Colon capsule is an ingestible miniature camera that captures images of the colon's inner lining. There is limited evidence on the use of this technology in imaging the colon. Two small, methodologically flawed pilot studies found that for patients with positive findings (i.e., abnormalities detected), the rates of detection with...

  • Project Number: E0034

Continuous Erythropoietin Receptor Activator (Mircera®) for Renal Anemia

Last Updated: February 12, 2008
Result type: Reports

Continuous erythropoietin receptor activator (CERA) is a third-generation erythropoiesis stimulating agent (ESA). CERA is used to correct anemia and maintain hemoglobin levels in patients with renal (kidney) failure. CERA is administered either once every two weeks (to correct anemia) or once per month (to maintain hemoglobin levels). This of...

  • Project Number: E0025

Optical Scanners for Melanoma Detection

Last Updated: March 31, 2014
Result type: Reports

The key to a melanoma cure is early detection before the cancer has spread beyond the epidermal skin layer. Several novel, hand-held, automated optical scanning devices have been developed to aid care providers in early diagnosis. These technologies quickly and non-invasively permit visualization deeper into the skin to detect evidence of mal...

  • Project Number: EH0008

Infrared Thermography for Population Screening and Diagnostic Testing for Breast Cancer

Last Updated: March 23, 2012
Result type: Reports

Thermography is a non-invasive diagnostic imaging tool that uses infrared thermal technology to detect variations of temperature on the human skin surface that may be attributed to cancer. No randomized controlled trials have been conducted that compare the effectiveness of thermography with mammography for screening in well women, and there ...

  • Project Number: EH0002

Obstructive Sleep Apnea: A Palatable Treatment Option?

Last Updated: January 30, 2007
Result type: Reports

The Pillar® Palatal Implant System consists of three polyester threads that are permanently implanted in the palate (the roof of the mouth) to reduce airway obstruction in individuals with mild to moderate obstructive sleep apnea (OSA) and snoring. Three small, non-randomized uncontrolled trials reported a moderate reduction in the number of ...

  • Project Number: E0008

Afrezza Inhaled Insulin for Diabetes Mellitus

Last Updated: January 23, 2013
Result type: Reports

Afrezza is a drug-device combination consisting of Technosphere insulin (TI) inhalation powder and a product-specific breath-activated inhaler. TI cartridges are used with an inhaler one minute before eating for managing type 1 and type 2 diabetes. TI significantly reduces postprandial glucose and glycated hemoglobin (A1C) levels in type 2 di...

  • Project Number: EH0003

Nuchal Translucency Measurement in First Trimester Down Syndrome Screening

Last Updated: June 27, 2007
Result type: Reports

Approximately three in every four fetuses with Down syndrome have increased nuchal translucency (NT), which is a larger than normal build-up of fluid at the back of the neck. The ultrasound measurement of NT between 11 and 14 weeks' gestation, in combination with the mother's age and the levels of placental biochemical markers in her blood, c...

  • Project Number: E0021

Sipuleucel-T (Provenge®): Active Cellular Immunotherapy for Advanced Prostate Cancer

Last Updated: August 31, 2007
Result type: Reports

Sipuleucel-T (Provenge®) is an active cellular immunotherapy (therapeutic vaccine) that is designed to stimulate the patient's T-cells to recognize and attack prostate cancer cells that express prostatic acid phosphatase (PAP) antigen. Sipuleucel-T demonstrated a survival benefit in men with advanced androgenindependent prostate cancer (AIPC)...

  • Project Number: E0037